Psyence Group Inc. · OTC:PSYGF
Psyence — Psyence Therapeutics — SPAC Merger (January 2023)
41 slides from Psyence's SPAC merger presentation, Jan 10, 2023
Slide 1: Corporate Presentation
CSE: PSYG | OTCQB: PSYGF Corporate Presentation
Slide 2: Cautionary Statement
1 CSE: PSYG | OTCQB: PSYGF Corporate Presentation Readers are therefore cautioned not to place undue reliance on such forward - looking statements . In addition, in considering any prior performance information contained in this presentation, readers should bear in mind that past results are not nec
Slide 3: Executive Summary
2 CSE: PSYG | OTCQB: PSYGF Corporate Presentation Executive Summary Licensed producer of natural psilocybin • Psyence Therapeutics is a wholly owned subsidiary of PSYENCE (CSE:PSYG) • Focussed on the development of natural psilocybin for the treatment of Adjustment disorder in palliative care • Stro
Slide 4: The Psyence Group Revenue and Value Creation
3 CSE: PSYG | OTCQB: PSYGF Corporate Presentation The Psyence Group Revenue and Value Creation Licensed producer of natural psilocybin Capital Markets Strategy EXPANDING PRESENCE IN NORTH AMERICA Team Functional Mushrooms Medical Team Capital Markets Production Experienced and Track Record Drug Deve
Slide 5: Acquisition Target
4 CSE: PSYG | OTCQB: PSYGF Corporate Presentation Acquisition Target Licensed producer of natural psilocybin Drug Development
Slide 6: Psyence Management Team
5 CSE: PSYG | OTCQB: PSYGF Corporate Presentation Xan Morgan DIRECTOR OF EUROPEAN OPERATIONS Successfully co - founded multinational businesses across water technology and electric sports cars, medical cannabis including holding Schedule 1 Controlled Drugs Licenses in UK. Tony Budden CHIEF STRATEGIC
Slide 7: Newcourt Management Team
6 CSE: PSYG | OTCQB: PSYGF Corporate Presentation Dan Rogers CHIEF FIANNCIAL OFFICER • CEO of FintechForce, Inc. • Former CFO of Endpoint Clinical • Former CFO of Simplee • Former CFO of Fifth Third Processing Solutions • Former VP, Wells Fargo Merchant Services Marc Balkin CHIEF EXECUTIVE OFFICER •
Slide 8: Domain Experts in Partnership with Experienced SPAC Dealmakers
7 CSE: PSYG | OTCQB: PSYGF Corporate Presentation Domain Experts in Partnership with Experienced SPAC Dealmakers Leveraging FTAC Experience FTAC Olympus Acquisition Corp. $750mm merged with Payoneer FTAC Parnassus Acquisition Corp. $250mm SPAC FTAC Zeus Acquisition Corp. $440mm SPAC Locust Walk Acqu
Slide 9: Market Disruptor: Psychedelics are making headlines
8 CSE: PSYG | OTCQB: PSYGF Corporate Presentation Psychedelics are making headlines: Market Disruptor
Slide 10: Psychedelics are making headlines
9 CSE: PSYG | OTCQB: PSYGF Corporate Presentation Market Disruptor Psychedelics are making headlines “We believe psychedelics could usher in a new era of neuroscience in which the insights gleaned through functional neuroimaging over the last twenty years will be leveraged to solve some of the long
Slide 11: Psyence Stands Out Against Competitive Landscape
10 CSE: PSYG | OTCQB: PSYGF Corporate Presentation Product Maturity Market Cap (mm) Pre - clinical Phase I Phase II Phase III 8.6 4.4 8.9 16.8 23.3 63.9 84.7 100.9 331.7 447.9 Commentary • Psyence’s core focus is on psilocybin - assisted psychotherapy for palliative care • The global palliative care
Slide 12: Psyence at a glance
11 CSE: PSYG | OTCQB: PSYGF Corporate Presentation Psyence (CSE:PSYG) is a life science biotechnology company pioneering the use of natural psychedelics in mental health and well - being. Our vision Psyence develops and will provide innovative, safe, and effective psychedelic and nature - centered s
Slide 13: Developing proprietary natural psilocybin for palliative care
Developing proprietary natural psilocybin drug development and treatment protocols with a focus on palliative care
Slide 14: Psyence is changing the face of palliative care treatment
13 CSE: PSYG | OTCQB: PSYGF Corporate Presentation Naturally Derived Plant based Psilocybin In Licensed IP Exclusive to USA, EU, UK 9 Patents granted Accelerated Outsourced drug Development PhIIb PhIII Size of Palliative Care Market 2030 Forecasted Year of commercialization of Pallicybin** $10.4B US
Slide 15: The Palliative Care Market
CSE: PSYG | OTCQB: PSYGF Corporate Presentation The Palliative Care (PC) Market Palliative care refers to care for patients and their families who are facing a serious, life - limiting illness. Palliative care is patient - centred coordinated care that aims to relieve suffering and improve quality o
Slide 16: Cancer share of palliative care opportunity
15 CSE: PSYG | OTCQB: PSYGF Corporate Presentation 15 Cancer will be approx. 37% of total chronic diseases in palliative care. Large opportunity to grow into other conditions Up to 40%* of cancer patients meet criteria for a mood disorder (*Holland et al., J Natl Comp Cancer Network: JNCCN 11: 190 –
Slide 17: Large Palliative Care Market with Robust CAGR
16 CSE: PSYG | OTCQB: PSYGF Corporate Presentation Large Palliative Care Market with Robust CAGR Cancer = 37% of Total PC Market Partial Accessible Market Global Palliative Care Market $28.6B with 9.8% CAGR (2030) Number of Cancer Patients Globally 21.7M (2030) Global Psychedelic Therapeutics Market
Slide 18: Estimated Total Addressable Market
17 CSE: PSYG | OTCQB: PSYGF Corporate Presentation Large Palliative Care Market with Robust CAGR Market Share % PAP Pricing ** Psilocybin Cost only $ 6,000.00 $ 500.00 1% $135m $11.25m 2% $270m $22.5m 5% $675m $56.25m 10% $1.35 B $112.5m Estimated Total Addressable Market Global Palliative Care Mark
Slide 19: Potential Health Economic Downstream Benefits
Palliative care reduces emergency room visits and total hospital days among patients with metastatic HPB and GI cancers | Scientific Reports (nature.com) Potential Health Economic Downstream Benefits
Slide 20: Target Indication with Palliative Care Population
19 CSE: PSYG | OTCQB: PSYGF Corporate Presentation Target Indication with Palliative Care Population • Pallicybin (Psilocybin) is indicated for the relief of symptoms of Adjustment Disorder caused by the diagnosis of a terminal illness, or • Pallicybin in conjunction with psychotherapy program is in
Slide 21: Adjustment Disorder
20 CSE: PSYG | OTCQB: PSYGF Corporate Presentation Adjustment Disorder Adjustment Disorder falls into the wide categorical spectrum of anxiety and depressive disorders. The DSM - 5 - TR criteria describes adjustment disorder as a development of emotional or behavioural symptoms in response to an ide
Slide 22: Academic Studies give Confidence of Rapid, Marked & Sustained Effect
21 CSE: PSYG | OTCQB: PSYGF Corporate Presentation Academic Studies give Confidence of Rapid, Marked & Sustained Effect Paper Published Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life - threatening cancer: a randomized controlled
Slide 23: Identified Clinical Papers of Relevance
22 CSE: PSYG | OTCQB: PSYGF Corporate Presentation Identified Clinical Papers of Relevance Paper Published Source : https://clinicaltrials.gov/ct2/show/NCT05398484?term=NCT05398484&draw=2&rank=1
Slide 24: Relevant Clinical Trials
23 CSE: PSYG | OTCQB: PSYGF Corporate Presentation Relevant Clinical Trials
Slide 25: Product
24 CSE: PSYG | OTCQB: PSYGF Corporate Presentation Product
Slide 26: Licensed Filament Health patented technology
25 CSE: PSYG | OTCQB: PSYGF Corporate Presentation • Psyence has Licensed in the Filament Health Patented technology • PEX 010 is the API for Development and commercialization • Naturally Derived Psilocybin • IP protected – 9 FDA and Health Canada granted Patents • Global Research and Commercial lic
Slide 27: About PEX-010
26 CSE: PSYG | OTCQB: PSYGF Corporate Presentation 26 Patent protected Licensed API Drug Development About PEX - 010 IMP: - Botanically - Derived Psilocybin Administration Route: - Oral In - licenced from Filament Health: Target Indication Adjustment Disorder associated with Terminal Cancer Diagnosi
Slide 28: Benefits of Natural Psilocybin Mushrooms
27 CSE: PSYG | OTCQB: PSYGF Corporate Presentation Psyence is cultivating psilocybin mushrooms (psilocybe cubensis). Our natural psilocybin mushroom products are: 1 https://www.cbi.eu/market - information/natural - ingredients - health - products/trends 2 https://www.grandviewresearch.com/industry -
Slide 29: Differentiated Strategy
28 CSE: PSYG | OTCQB: PSYGF Corporate Presentation 28 Differentiated Strategy Psyence Target Indication Adjustment Disorder associated with Terminal Cancer Diagnosis Adjustment disorder is a serious condition affecting 40% of patients with a terminal diagnosis. Psychedelic Sector** • First mover in
Slide 30: Clinical Development Program for Palliative Care
Clinical Development Program for Palliative Care
Slide 31: Driving our Clinical Program
30 CSE: PSYG | OTCQB: PSYGF Corporate Presentation Driving our Clinical program: • Rigorous clinical trials to prove efficacy and safety • Partnership with Clerkenwell Health – MHRA [Medicines and Healthcare Products Regulatory Agency] for clinical trials in the UK • Large total market with robust C
Slide 32: Psychedelic-Assisted Psychotherapy (PAP)
CSE: PSYG | OTCQB: PSYGF Corporate Presentation Psychedelic - Assisted Psychotherapy (PAP) The current standard of care in most uses of psychedelic medicines for the treatment of psychiatric indications includes the provision of a supportive therapeutic context before, during, and after drug adminis
Slide 33: UK Clinical Trial Phase IIa
32 CSE: PSYG | OTCQB: PSYGF Corporate Presentation UK Clinical Trial Phase IIa Psyence’s clinical trial program is focused on assessing the safety and efficacy of psilocybin - assisted psychotherapy for the treatment of adjustment disorder* due to an incurable cancer diagnosis versus psychotherapy a
Slide 34: Proposed Phase IIb Trial Format
33 CSE: PSYG | OTCQB: PSYGF Corporate Presentation Proposed Phase IIb Trial Format A Phase IIb Randomized, Double - blind, Placebo - controlled, Study of the Effects of Psilocybin - assisted Psychotherapy on Adjustment Disorder in terminal cancer patients: • Assess safety, efficacy and tolerability
Slide 35: Updated Regulatory Pathway to Approval
34 CSE: PSYG | OTCQB: PSYGF Corporate Presentation 34 Updated Regulatory Pathway to Approval Phase IIB, to be conducted in Australia.
Slide 36: Psyence Therapeutics Strategic R&D Plan
35 CSE: PSYG | OTCQB: PSYGF Corporate Presentation Pre - clinical Observational Phase I Phase II Phase III 2023 – 2025 Psyence Therapeutics Strategic R&D Plan Clinical Trial Phases * In Planning # Details to be released after results known FPFV= First patient, First visit FSR= Final Study Report Pal
Slide 37: Psyence's Intellectual Property within Drug development
36 CSE: PSYG | OTCQB: PSYGF Corporate Presentation Psyence’s Intellectual Property within Drug development May 2022 Q4 2022 Q4 2022 Regulatory Protection Data and Marketing Exclusivity: • First indication with Molecule will be granted protection from any generic entry for periods up to 10 years • Up
Slide 38: In Summary
37 CSE: PSYG | OTCQB: PSYGF Corporate Presentation In Summary Licensed producer of natural psilocybin • Psyence Therapeutics, developing natural psilocybin for the treatment of Adjustment Disorder in palliative care, is combining with NewCourt SPAC • The two companies have entered into a Business Co
Slide 39: Risk Factors relating to Psyence's business
38 CSE: PSYG | OTCQB: PSYGF Corporate Presentation Readers are therefore cautioned not to place undue reliance on such forward - looking statements . In addition, in considering any prior performance information contained in this presentation, readers should bear in mind that past results are not ne
Slide 40: Back up Slides
39 CSE: PSYG | OTCQB: PSYGF Corporate Presentation Back up Slides
Slide 41: Supportive literature PAP
Supportive literature PAP • “The first wave of psychedelic medicines in psychiatry will almost certainly hold as axiomatic that psychedelic medicines are best administered within a well - considered context of psychotherapy.” * Brennan W and Belser AB (2022), Models of Psychedelic - Assisted Psychot